Presenting Companies

BioCapital Europe – March 9th 2023

Event organized by 



VarmX’s lead compound VMX-COO1 is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors.

Synthetic oral factor Xa inhibitors (such as edoxaban, rivaroxaban and apixaban) belong to the latest generation of anticoagulants and their world-wide use by patients at risk of thrombosis and stroke is increasing rapidly. However, usage of factor Xa inhibitors comes at the expense of a risk of uncontrolled and potentially life-threatening bleeding. To stop or prevent – the latter in the case of emergency surgery – these bleedings one needs a reversal agent as an antidote. VarmX has a product in its pipeline called VMX-COO1 that promises safe and effective reversal.


ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The company’s first FDA pivotal trial, called Up-LIFT, completed enrollment December 2021 with 65 subjects worldwide. ONWARD’s technology is protected by over 310 issued or pending patents globally.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains a significant team in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit To access our 2022 Financial Calendar, please visit


Ultimovacs is a biotech company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.

Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is a limited public liability company listed on the Oslo Stock Exchange in Norway.

Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden. Ultimovacs is an active member of Oslo Cancer Cluster.

Ultimovacs seeks to become a leader in developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 leverages the high prevalence of the human telomerase (hTERT) to be effective across the dynamic stages of the tumor’s growth and its microenvironment. By directing the immune system to hTERT antigens that are present in over 80% of all cancers, UV1 drives CD4 helper T cells to the tumor with the goal of activating an immune system cascade to increase anti-tumor responses. Ultimovacs’ strategy is to clinically demonstrate UV1’s impact in many cancer types and in combination with other immunotherapies. The Company will expand its pipeline using its novel TET-platform, which is a next-generation vaccine technology that can generate multiple vaccine candidates designed to achieve increased T cell responses to a broad range of target antigens.

iSTAR Medical

iSTAR Medical, founded in 2011 and headquartered in Wavre, Belgium, is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma. Glaucoma is the second leading cause of adult blindness globally, affecting more than 90 million people. Micro-invasive glaucoma surgery (MIGS) is the most promising and fastest-growing therapeutic option in the treatment of glaucoma.

iSTAR’s lead product, MINIject ™, has been designed to be a best-in-class MIGS device. Data from its first-in-human STAR-I trial confirms that it is safe and highly effective in achieving significant IOP reduction, as well as easing medication burden in glaucoma patients. Several additional studies are in progress to support iSTAR’s market entry plans into Europe and the United States.
iSTAR has raised €55 million to-date.


Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur, and Dr Eliane Piaggio PhD, Director of the Translational Immunotherapy Team at Institut Curie, Egle Therapeutics is developing first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.

Our Science
Egle’s scientific foundations benefits from decades of breakthrough academic research leading to unprecedented computational based IL-2 modified variants and a unique translational-based target discovery platform unveiling novel therapeutic Treg targets.

The key element of Egle’s core approach leverages of unifying therapeutic potentials of antibody specific targeting combined with the selective mechanism of action of modified cytokine for arming or disarming the most immunosuppressive Tregs to restore the immune response.

Egle deploys its first-in-class technology platforms to building a furnished drug pipeline of novel immunotherapies against Tregs with tremendous potential in the oncology and auto-immunity fields.



Patients with neurological disorders need an accurate, early diagnosis for better quality of life for them and their families/caregivers. We aim to continue to innovate new ways to support clinicians in providing the best care for their patients.
With a long, collective history of science and research, we combine our knowledge of neurological conditions, passion for innovative technology like artificial intelligence, and insights from our partnerships with clinical care centers to develop new solutions that fill the gaps in clinical care.
When we hear from current customers that cNeuro has provided the information they need for confident, evidence-based decisions for their patients, we know that we’re on the right track. Yet, we are constantly looking forward to addressing the next challenge, whether that’s aiding with patient selection for clinical trials of disease-modifying drugs for Alzheimer’s disease or putting tools directly in the hands of patients.
Based in Finland, we take pride in our Nordic background and close relationships with leading institutions in the area as well as in the international community.

Sequana Medical NV

Sequana Medical NV is a commercial stage medical device company developing the alfapump® platform for the treatment of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a fast growing complication of advanced liver disease driven by NASH (non-alcoholic steatohepatitis) related cirrhosis and a common complication in heart failure with diuretic resistance being widespread in both of these indications.
Both indications leverage Sequana Medical’s alfapump, a unique, fully implanted wireless device that automatically pumps fluid from the abdomen into the bladder, where it is naturally eliminated through urination. The alfapump has been granted FDA breakthrough device designation for recurrent and refractory ascites due to liver cirrhosis with a pivotal study in the U.S. and Canada (POSEIDON) underway, and is approved in Europe for refractory ascites due to liver cirrhosis and malignant ascites. Over 800 alfapump systems have been implanted to date. The alfapump DSR® (Direct Sodium Removal) builds on this experience and is in development as a potential chronic therapy for fluid overload in heart failure. Clinical proof-of-concept was achieved and strong interim results have been published from an ongoing repeated dose alfapump DSR study (RED DESERT) in diuretic-resistant heart failure patients.

Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit:


Perfuze is an interventional neurovascular company focused on Acute Ischemic Stroke. Perfuze has developed super-bore diameter aspiration technology that has the capability to navigate the complex neurovascular anatomy. Perfuze’ pipeline of products are designed to facilitate fast, complete clot removal from the brain during acute ischemic stroke. Perfuze has CE Mark approval for its first device, Millipede 088 and has successfully treated its first cohort of patients.

Amolyt Pharma

Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.

NewAmsterdam Pharma

At NewAmsterdam Pharma, we are passionate about providing transformational therapies for patients suffering from an array of conditions where aberrant cholesterol metabolism still underlies significant morbidity and mortality. We are developing safe, convenient, oral medications for metabolic diseases to help transform the treatment paradigm for these patients.

Our lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP) which has been clinically shown to significantly reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). CETP functions to transport cholesterol from ‘good’ HDL to ‘bad’ LDL. Obicetrapib works by blocking this transfer, thus substantially lowering LDL while simultaneously increasing HDL. We believe by transforming the ratio of ‘good’ versus ‘bad’ cholesterol in the body, obicetrapib holds transformative treatment potential for patients.



Nobi is a smart lamp. Its motto? Happiest at home. Its mission? Create technology that helps elderly people to live their lives in happiness, dignity and independence. At home, in a serviced flat or a nursing home – wherever people need care, Nobi ads quality and efficiency. Nobi is a guardian angel, with fall prevention and fall detection, but also with fire and burglar alarms or continuous health monitoring. Nobi was launched in 2018 in Belgium by a team of seasoned smart home and elderly care entrepreneurs. Today, the company is expanding in the EU and has opened its first office in the US.


Calliditas Therapeutics

Calliditas Therapeutics is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications, where the company can partially or completely participate in the commercialization. Initial focus is in renal and hepatic indications.


Aelin Therapeutics

Aelin Therapeutics secured a 27 M€ Series A investment to exploit its proprietary Pept-in™ protein knockdown platform as a novel modality in drug development. Company will exploit its proprietary platform technology to develop a new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets in oncology. The Peptin technology harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein. The technology allows for the rational design of novel biotherapeutics and differentiates itself from any other therapeutic modality through its unique mode of action, its designability and intracellular target space out of reach for other therapeutics.


T-knife Therapeutics

T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company’s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity.

T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin. For additional information, please visit the company’s website at


NewAmsterdam Pharma

Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, allows individualised treatments to target and destroy tumours without harming healthy tissues.



Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

PHA121, Pharvaris’ lead drug candidate, is a novel, potent small-molecule bradykinin B2 receptor antagonist. PHA121 is the only oral B2-receptor antagonist in clinical development, currently under Phase 1 clinical study.

Pharvaris was founded in October 2015 by executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.



BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression. This is a large paradigm shift from today’s symptom-oriented therapies.

BioArctic’s proprietary technology platform, dedicated personnel, collaborations with leading academic research groups and the global pharma industry have made it possible to develop innovative treatments based on antibodies (immunotherapy) for neurodegenerative disorders.



Despite technological advances, ablation treatment for the millions of patients suffering with AFib is only successful in around half of patients. OneProjects are developing VERAFEYE, a novel endovascular catheter system to increase the efficacy and safety of cardiac ablations. VERAFEYE, utilizing advanced imaging and analytics in conjunction with its innovative catheter-based sensor system, is a connected technology generating unprecedented 4D data during the cardiac ablation procedure. By providing the physician with real-time high resolution anatomical maps of the cardiac structures and beyond, VERAFEYE will aid in therapy planning (cardiac wall thickness/morphology etc.) and also include imaging of ablation lesions as they are created in the heart muscle to increase the efficacy as well as the safety of catheter ablation.

The company vision is to provide data of unparalleled data to physicians to make effective treatment accessible to the growing number of patients worldwide while reducing cost to the healthcare system.
OneProjects offices are located in Dublin, Ireland and Munich, Germany.



FundamentalVR is a healthcare technology company with a mission to accelerate human capability via precision simulation and as a result, advance pre-human competence in surgery and additional clinical environments to improve patient outcomes.

We partner with medical device, pharmaceutical companies, and healthcare systems to enhance skills acquisition and training globally.

Through our platform Fundamental Surgery, we offer a range of skills and training experiences that facilitate remote and immersive medical training within a virtual reality (VR) environment.

These VR experiences provide situational awareness and allow teams to remotely collaborate, rehearse, and practice in a frictionless, ‘plug and pay’ way.

Our HapticVR™ environments and experiences deliver the gold standard for skills transfer, allowing users to physically interact with a virtual patient. HapticVR™ enables users to develop the knowledge of how it feels to perform a procedure correctly or incorrectly – helping to build muscle memory that is particularly important in advanced and precise surgical environments. Our haptic technology has been shown to improve accuracy and skills development.



ViCentra B.V. - CMOCRO

We want to make sure people with diabetes have a voice. And we feel it’s so important that we listen. That’s why, alongside making Kaleido, we’ve made strong links within the diabetes community. As well as checking in often with our current and potential users, we work with other organizations, like our friends at Diabeloop and JDRF, to help develop ideas and continue to make things better for those rocking Type 1.

We know that creating brilliant products doesn’t end in the lab though – we also believe in the power of great customer experiences. So, we’re creating healthcare products with this philosophy firmly in mind. At ViCentra, we don’t design for patients – we design for people. 


ImCheck Therapeutics | Gimv

ImCheck Therapeutics is designing and developing novel immunotherapeutics that target members of the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules with an initial focus on gamma delta (γ9δ2) T cells. ImCheck’s understanding of these novel targets benefits from the continued involvement of company scientific founder Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille University), a world-renowned researcher in γ9δ2T cells and BTNs, which has led to identification of additional immune cell populations that can be modulated through BTN(L)s, including tumor associated macrophages (TAMs).

ImCheck’s expertise in antibody-based drug discovery and translational research have enabled us to advance our first immuno-oncology program targeting BTN3A to activate γ9δ2T cells into the clinic in 2020 and to produce a broad pipeline of monoclonal antibody drug candidates.

Due to their mechanism of action, including the ability to simultaneously modulate innate and adaptive immunity, ImCheck’s “first-in-class” antibodies may be able to improve upon the first-generation of checkpoint inhibitors in cancer. ImCheck’s programs also have potential in autoimmune and infectious disease indications, which the company is currently investigating. 



Nouscom AG – Swiss Biotech

Backed by international life sciences investors, Nouscom was founded in 2015 and is headquartered in Basel, Switzerland. A clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies, Nouscom uses a proprietary viral vector platform which has the capacity to encode for large payloads of neoantigens to safely and potently harness the power of the immune system. 6 clinical trials are actively ongoing, including a randomized Phase 2 trial of NOUS-209 for the treatment of MSI-H solid tumors in combination with pembrolizumab, a Phase 1b ‘cancer interception’ in Lynch Syndrome as well as NOUS-PEV, a personalized cancer immunotherapy that will be reporting Phase 1 data at a forthcoming scientific conference in Q2 2023. Nouscom has also exclusively out-licensed a third product, VAC-85135, to Janssen Oncology, which is currently under evaluation in a Phase 1 trial.




Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer’s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis.





SNIPR Biome is pioneering a novel use of CRISPR/Cas technology for microbial gene therapy. Our focus is on the development of novel, highly selective anti-bacterial drug candidates for use in difficult-to-treat conditions.

Our CRISPR-based technology can very precisely target specific “bad” bacteria in the gut without affecting the “good” bacteria of the resident microbiota.

This platform leverages two naturally derived technologies that originated in bacteria (bacteriophages for delivery, CRISPR/Cas for killing), both of which create an advantage in terms of selectively targeting specific bacterial species.  


Image is not available

Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases. The company’s unique technology platform has the potential to address a wide range of indications in the vast field of immunology with active development programs ongoing in T1D, multiple sclerosis, rheumatoid arthritis, neuromyelitis optica and celiac disease. The technology is based on the administration of modified synthetic peptides – ImotopesTM, which specifically block improper immune responses. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense.



Ordering RNA can be an intricate process, so whether you’re interested in research grade material or in GMP production, the eTheRNA manufacturing team are happy to support and guide you through the process. Our standard approaches and processes are scalable, from mg to g level, and we produce according to customer specification and with clinical phase appropriate controls.

Our services include plasmid development and production, research grade mRNA production and GMP grade mRNA production, including a wide range of options for purification and QC.
Based upon experience with own clinical trials, eTheRNA manufacturing can also provide support in stability studies, purification and analytical method development and CMC file writing. 



Oculis is a global biopharmaceutical company purposefully driven to save sight
and improve eye care with breakthrough innovations.

One of our most advanced product candidates, OCS-01, has successfully completed a Phase 2 trial in DME (DX-211) with 144 patients providing the first proof-of-concept for a topical drug effect in retinal edema. If approved in DME, it has the potential to provide a new and potentially the FIRST non-invasive option for patients.

OCS-01 also successfully completed another Phase 2 trial in Inflammation and Pain following cataract surgery. Following the completion of both Phase 2 trials, an End of Phase 2 meeting was conducted with FDA and the product candidate is now moving into phase III in both indications.

OCS-01 has been developed using the OPTIREACH solubilizing nanoparticle (SNP) technology, a proprietary platform that enables the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.  


Vivasure Medical Limited is a highly innovative medical device company based in the heart of Europe’s largest medtech hub in Galway, Ireland. The company develops advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery.

Established in 2009, Vivasure operates a fully integrated, ISO 13485 certified, R&D and manufacturing facility. The company is staffed by an experienced team of medical device professionals with expertise spanning research, engineering, material science, quality, regulatory, manufacturing, clinical and commercial roles. 


Xeltis Logo


Xeltis is a clinical-stage medical device company with the most advanced polymer-based restorative devices for cardiovascular treatment.

Xeltis’ devices naturally evolve into living blood vessels or heart valves, when colonised by patient’s own tissue. 


Investment Portfolio | Lumeon | Amadeus Capital Partners

Lumeon is a digital health company dedicated to helping provider organisations mend broken care coordination processes through automated care orchestration.

Lumeon’s  award-winning care orchestration platform has proven to deliver demonstrable results, in as little as 90 days.

Leading providers in the U.S. and Europe are embracing Care Orchestration to: 



ORYZON is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology.

Our business model is to develop our proprietary drug candidates through clinical Phase II, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization.

ORYZON has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks.   

LeoCancer Care

Leo Cancer Care

Leo Cancer Care was founded with more than 100 years of Radiation Therapy experience by a team dedicated to challenging the norms in everything we do.

Patients’ lives influence us to find a better way, a better way to improve patient care and how a patient experiences it. A better way to increase the accessibility of cancer treatments for more patients in more places. We believe our technology is that better way. Our family of world class products can provide a streamlined and efficient treatment while making the patient feel in control and hopeful.

Originally founded in Australia, Leo Cancer Care has been built on research from across the globe showing the clinical benefits of upright patient positioning. Combining this with a shift from machine rotation to patient rotation, Leo Cancer Care is set to change the face of Radiation Therapy for good. 


Med Technology Endovascular Surgery. Critical limb ischemia - Versono

Versono Medical is an early stage Irish MedTech company located in Galway, a global centre for excellence in medical technologies. The company collaborates with clinicians and research institutions across the world.

The company’s focus is on developing and commercialising a new technology platform for endovascular surgery that will focus initially on patients with Critical limb ischemia CLI, the most severe and advanced clinical manifestation of Peripheral Arterial Disease PAD. Versono’s mission is to enable endovascular treatment of Complex Chronic Lesions to alleviate pain, save limbs and save lives in order to address poor patient outcomes, high amputation and high mortality rates associated with CLI.

The technology targets severe occlusions in CLI patients, which presents one of the most challenging unmet needs in peripheral endovascular surgery. Versono’s product is designed to efficiently revascularize the lesion and present an avenue for subsequent therapeutic interventions to improve patient outcomes 

Vico Therapeutics

 VICO Therapeutics - VICO Therapeutics


Our mission is simple… bring innovative RNA modulating therapies to patients with genetic neurological diseases.

Our vision is to become a recognised leader in developing antisense oligonucleotide RNA modulators for genetic neurological disorders and to establish an organization that fosters positive and collaborative relationships with patients, physicians, partners, community members and our fellow employees. 


 Immunic Therapeutics


Immunic is currently pursuing three development programs. These include:

  • the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase, or DHODH;
  • the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated, or RORγt, an immune cell-specific isoform of RORγ;
  • and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium.

These product candidates are being developed to address diseases such as multiple sclerosis, psoriasis and gastrointestinal diseases. 

FoRx Theraptuics

FoRx Therapeutics


FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment.
FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs. FoRx scientists bring more than 20 years of experience in DNA replication stress and DNA Damage Response pathways. Our team consists of scientists and advisors with extensive experience in cancer biology, cancer genomics, biochemistry, medicinal chemistry and small molecule drug discovery. FoRx is located in Basel, Switzerland, a world-leading hub of biotech and pharmaceutical industry.




At AviadoBio our mission is to transform the lives of patients living with and suffering from neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Our industry-leading science and technology is based on pioneering research from King’s College London and the UK Dementia Research Institute, co-founded by Prof. Christopher Shaw, Dr. Youn Bok Lee and Dr. Do Young Lee and is supported by leading life sciences investors.

We are building world-class capabilities to discover, develop, manufacture and commercialise gene therapy products.

DNA Script

 法国颠覆性DNA合成公司:DNA Script SAS | 美股之家| 美股百科| 美港股开户投资

DNA Script was created to revolutionize DNA writing with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become a major engine of genomics research and personalized medicine. 


 Cardior - Sunstone


Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide. 

AC Immune

 AC Immune SA - World-class science that makes a difference in patients' lives 


AC Immune is a clinical-stage biopharmaceutical company emerging as a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases.

Since AC Immune’s foundation in 2003, our staff has developed pioneering scientific and clinical expertise in the understanding and treatment of neurodegeneration. Our deep knowledge and cutting-edge technology platforms, SupraAntigen® and Morphomer®, are the engines for our diverse pipeline of clinical and preclinical product candidates.

Our experienced management team combines outstanding scientific, clinical, regulatory, financial and corporate development competencies to build on the seminal work of AC Immune’s founders.

The Board of Directors includes leading industry veterans, who oversee and optimise our corporate strategy and execution. We also benefit from working closely with collaboration partners, investors, clinicians and academic researchers. 



Founded in 2007, Phagenesis is committed to scientific and clinical excellence in the development of novel therapies to treat patients suffering from neurogenic dysphagia.
The foundational science and clinical evidence for the pharyngeal electrical stimulation used in Phagenyx, has been peer reviewed and published at the highest level.
Onera Health


Founded in 2017, in Eindhoven, The Netherlands, Onera Health is a spin-off of imec research center, a leader in nanoelectronics and digital technologies.

Headquartered in Eindhoven, with operations all over the globe, Onera Health’s ambition is to empower healthcare professionals with breakthrough solutions, to ultimately improve the health and quality of life of their patients.
Binx Health

Amid National Surge in Sexually Transmitted Infections binx health  Announces Launch of Reagent Rental Program for Decentralized, Rapid,  Point-of-Care Testing Platform for Chlamydia and Gonorrhea | Business Wire

Binx health is a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care. The binx io platform is the first ever FDA-cleared, CLIA-waived point-of-care tool for the detection of chlamydia and gonorrhea from male and female specimens that provides central lab performance results in about thirty minutes. The platform is highly flexible, easy-to-use, and rapid, offering molecular point-of-care answers at central-lab quality performance,  enabling single-visit test and treatment.

For more information, visit



We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs.

Our focus and commitment to patients will always remain at the center of everything we do with the aim to add years of life and quality of life of patients across the globe.

Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications.Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

For additional information, please visit or follow us on LinkedIn or Twitter

Achilles Therapeutics



Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, allows individualised treatments to target and destroy tumours without harming healthy tissues.